NASDAQ: OTLKOutlook Therapeutics Inc Stock
$0.44-0.02 (-4.35%)
Updated Jan 30, 2026
OTLK Price
$0.44
Fair Value Price
N/A
Market Cap
$28.21M
52 Week Low
$0.42
52 Week High
$3.39
P/E
-0.25x
P/B
-0.88x
P/S
26.1x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.41M
Earnings
-$62.42M
Gross Margin
4%
Operating Margin
-4,505.98%
Profit Margin
-4,416.2%
Debt to Equity
-1.58
Operating Cash Flow
-$52M
Beta
1.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OTLK Overview
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OTLK's potential to beat the market
- OTLK doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OTLK
RankedUnranked of 483
RankedUnranked of 483
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.58 | A | |
| $164.49 | A | |
| $20.47 | A |
Be the first to know about important OTLK news, forecast changes, insider trades & much more!
OTLK News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OTLK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OTLK is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OTLK is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
OTLK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more OTLK due diligence checks available for Premium users.
Valuation
OTLK fair value
Fair Value of OTLK stock based on Discounted Cash Flow (DCF)
Price
$0.44
Fair Value
-$0.80
Undervalued by
155.11%
OTLK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OTLK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.25x
Industry
168.05x
Market
43.06x
OTLK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.88x
Industry
5.44x
OTLK's financial health
Profit margin
Revenue
-$91.8k
Net Income
-$13.3M
Profit Margin
14,482.2%
OTLK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OTLK's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$18.6M
Liabilities
$50.8M
Debt to equity
-1.58
OTLK's short-term liabilities ($45.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OTLK's short-term assets ($17.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OTLK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OTLK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.4M
Investing
$0.0
Financing
$11.6M
OTLK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OTLK vs Biotech Stocks
Outlook Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.